Jefferies Group LLC restated their hold rating on shares of Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) in a report released on Monday. The firm currently has a $1.50 target price on the biotechnology company’s stock.

Several other research firms also recently commented on GNMX. ValuEngine downgraded shares of Aevi Genomic Medicine from a sell rating to a strong sell rating in a research note on Friday, June 2nd. UBS AG reiterated a positive rating on shares of Aevi Genomic Medicine in a research note on Wednesday, May 10th.

Aevi Genomic Medicine (GNMX) remained flat at $1.18 during midday trading on Monday. The company’s stock had a trading volume of 12,747 shares. The firm’s 50-day moving average price is $1.30 and its 200-day moving average price is $2.56. Aevi Genomic Medicine has a 1-year low of $0.98 and a 1-year high of $6.89. The company’s market cap is $43.79 million.

Aevi Genomic Medicine (NASDAQ:GNMX) last posted its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by $0.02. On average, equities research analysts expect that Aevi Genomic Medicine will post ($1.08) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/08/aevi-genomic-medicine-inc-gnmx-stock-rating-reaffirmed-by-jefferies-group-llc.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of GNMX. State Street Corp increased its position in Aevi Genomic Medicine by 15.4% in the fourth quarter. State Street Corp now owns 345,698 shares of the biotechnology company’s stock worth $1,789,000 after buying an additional 46,149 shares in the last quarter. LMR Partners LLP acquired a new position in Aevi Genomic Medicine during the second quarter worth about $149,000. TIAA CREF Investment Management LLC increased its position in Aevi Genomic Medicine by 16.7% in the first quarter. TIAA CREF Investment Management LLC now owns 97,719 shares of the biotechnology company’s stock worth $182,000 after buying an additional 13,966 shares in the last quarter. Birchview Capital LP increased its position in Aevi Genomic Medicine by 41.7% in the first quarter. Birchview Capital LP now owns 68,000 shares of the biotechnology company’s stock worth $126,000 after buying an additional 20,000 shares in the last quarter. Finally, Teachers Advisors LLC acquired a new position in Aevi Genomic Medicine during the fourth quarter worth about $204,000. Institutional investors own 27.97% of the company’s stock.

About Aevi Genomic Medicine

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn’s disease.

Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.